As described, PD-1, programmed death-ligand 1, is the most developed immune checkpoint inhibitor investigated in AML. Commonly used drugs in this drug class include nivolumab, pembrolizumab, and atezolizumab. Increased expression of PD-1 has been documented in subsets of populations such as relapsed/refractory (R/R) AML and demonstrates poorer outcomes. Therefore, patients with increased expression of PD-1 benefit from this immune checkpoint inhibitor therapy. Hypomethylating agents (HMA) are also used in the therapy of AML. These drugs work by inhibiting methyltransferase, altering gene expression (12). Recent studies have identified a correlation between HMA resistance and dysregulated PD-1/PD-L1 signaling. Higher levels of expression of PD-1/PD-L1 have been seen in patients with AML with no response to HMAs, which may represent a potential mechanism of resistance to this class of agents. Therefore, the efficacy of monoclonal antibodies targeting this pathway in HMA-failure myelodysplastic syndrome (MDS) or R/R AML is assessed. A nonrandomized, open-label phase II study by Daver et al. targeted PD-1 in combination with HMA in R/R AML [both HMA naïve (n=25) and HMA failure (n=45)] with nivolumab and azacitidine. They observed an overall response rate (ORR) of 33% (58% in HMA-naive and 22% in HMA-failure patients). Complete remission with incomplete count recovery (CR/CRi) was 22%, and median overall survival (OS) was 6.3 months with 22% grade >2 immune toxicities (13).

Pembrolizumab has also been evaluated in both newly diagnosed and R/R AML patients in combination with azacitidine by Gojo and colleagues (14). In the R/R cohort, the ORR was noted to be 18%, with 14% of patients experiencing CR/CRi and PR in 4% of patients with a median OS of 10.8 months for all patients. However, in newly diagnosed patients, the ORR was 59% (CR/CRi 47%; PR 12%) with a median OS of 13.1 months. Additionally, pembrolizumab has been evaluated with decitabine in R/R AML. This study was limited by a small number of patients (n=10). Stable disease was achieved by 4 patients, with 1 patient experiencing minimal residual disease and a negative CR. The median follow up was 13 months, with median OS of 7 months.

The role of PD-L1 blockade in combination with HMA in patients with AML has also been explored (15). Zeidan and colleagues randomized patients with newly diagnosed AML to receive azacitidine alone (n=64) vs. azacitidine in combination with durvalumab (n=65). The ORR was similar in both arms, with ORR of 31.3% in patients receiving azacitidine alone and ORR of 35.4% in patients receiving combination therapy. Unfortunately, no difference was observed in OS or duration of response between groups. The OS and duration of response for patients treated with single agent HMA were 13.0 months and 24.6 weeks, with the doublet cohort experiencing OS of 14.4 months and duration of response 51.7 weeks.

Lastly, intensive chemotherapy has also been evaluated in combination with anti-PD-1 therapy. A phase II single arm clinical trial conducted by Zeidner et al. examined PD-1 inhibition using pembrolizumab in combination with intensive chemotherapy (high dose cytarabine) in R/R AML. These authors demonstrated an ORR of 46% in the 37 patients treated with 38% of patients experiencing a composite complete remission rate, and a median OS of 11.1 months (15). Although much fervor has surrounded agents targeting PD-1 and PD-L1 in other malignancies due to impressive and durable responses, enthusiasm has waned for utilizing these agents in AML as a result of minimal improvement in responses and survival.

TIGIT, or T cell immunoreceptor with immunoglobulin and ITM domain; is a promising immune checkpoint (11). TIGIT is an immune checkpoint receptor part of the immunoglobulin (Ig) superfamily and is regulated by a plethora of immune cells such as NK cells, activated T cells, and regulatory T cells. CD155 and CD112 are expressed on tumor cells and antigen-presenting cells (APC) within the tumor microenvironment. TIGIT has two binding sites for these CD antigens. Studies have shown that TIGIT plays a role in regulating T and NK cell-mediated recognition. Although TIGIT inhibition alone has shown less impressive antitumor effects, dual blockade of TIGIT with PD-1 has demonstrated almost complete tumor rejection in murine tumor models, which is supportive of further investigation in patients with cancer.

Prior studies have found that the microenvironment of the leukemia bone marrow contains immunosuppressive factors promoting the evasion of leukemic stem cells from immunological surveillance. In a 2021 Xu L et al. study, findings showed higher co-expression of PD-1 and TIGIT in both CD4+ and CD8+ T cells in bone marrow samples of de novo AML patients compared to peripheral blood samples, supporting that there are increased immunosuppressive factors in bone marrow compared to peripheral blood ( Table 2 ) (16).

Brauneck and colleagues identified TIGIT as a target for macrophage-mediated cytotoxicity in AML. TIGIT was highly expressed on bone marrow-infiltrating immunosuppressive M2 macrophages within newly diagnosed and relapsed AML. Additionally, they found that in vitro blockade of TIGIT shifted the polarization of leukemic-associated macrophages from the M2 phenotype to the M1 phenotype. They also reported anti-CD47-mediated phagocytosis of AML cells augmented by TIGIT blockade (17).

Gournay and colleagues also demonstrated that high levels of TIGIT on CD4+ T cells three months after allogeneic HSCT was significantly associated with an increased risk of subsequent relapse in AML patients. Additionally, higher expression levels of TIGIT on CD8+ T cells were directly correlated with poorer clinical outcomes (18). These findings support that this immune checkpoint inhibitor is important in post-transplant relapse (19). Overall, TIGIT represents a potential target in AML. However, data supporting the pre-clinical or clinical activity of an agent targeting TIGIT remains to be seen.

Lymphocyte activation gene 3 (LAG3) is a co-inhibitory receptor belonging to the Ig superfamily, also known as CD223, which may be another promising immune checkpoint therapy for AML immunosuppression (20). It suppresses T cell activation and cytokine secretion and demonstrates synergism with PD-1 to inhibit an immune response. LAG3 is a promising target as it has shown efficacy against PD1-resistant AML in conjunction with PD1 therapy. Anti-LAG3 antibodies can upregulate effector T-cell activity and inhibit T-regulatory cell suppressive function.

In the 2019 study by Abdelhakim, H. et al., these authors found that AML cells promoted immunosuppression with higher expression of LAG3 on CD8+ T cells the in vitro model. Peripheral blood mononuclear cells were harvested from healthy donors and AML patients ( Table 2 ). Anti-LAG3 antibody attenuated this immunosuppression by increasing the number of activated T cells and cytotoxic cytokines, decreasing T-reg cells, and enhancing MHC-I mediated killing of AML cells, thus supporting the inhibition of LAG3 as a means to mitigating AML immunosuppressive effect (21).

Chen, C. et al. investigated the expression pattern of LAG3 and other immune checkpoints in AML using data from de novo AML patients within the TCGA database and AML bone marrow samples ( Table 2 ). They found that AML patients had poorer overall survival with high CTLA-4 and LAG3 expression (3-year OS 9% vs. 36% and 13% vs. 40%, respectively) (22).

Relatlimab is a monoclonal IgG4 antibody that blocks LAG-3. The Food and Drug Administration (FDA) recently approved it as a treatment for untreated advanced malignant melanoma. The AARON trial (NCT04913922) is a phase 2, open-label clinical trial within its recruiting phase to investigate the safety and efficacy of combination therapy with nivolumab, azacitidine, and relatlimab in R/R AML ( Table 1 ) (23). The results from this clinical trial will be pivotal in understanding whether targeting LAG-3 can enhance the activity of anti-PD-1 therapy in AML when combined with HMA.

T cell immunoglobulin and mucin domain 3, TIM3, is a cell surface molecule expressed on leukemia cells (24). In CD4+ and CD8+ T cells and leukemic cells, TIM3 overexpression may lead to poor response and relapse in patients; therefore, TIM3 inhibitors are currently being investigated as potential AML treatments. Regarding acute myeloid leukemia, studies have shown that leukemia stem cells (LSC) have higher expression of TIM3 but not in healthy hematopoietic stem cells (HSC). Therefore, targeting TIM3 with antibodies or microRNA can destroy LSCs without affecting healthy HSCs. In leukemic cells of AML, TIM3 participates in an autocrine stimulatory loop, which activates the β-catenin and NF-κB pathways integral for cell survival and disease progression. Moreover, TIM3 inhibitors induce cell apoptosis in AML (24).

Additionally, Al-Amrani, S. et al. (2022) have shown that there is a higher expression of TIM3 in peripheral blood of AML cell lysates compared to healthy controls with median concentration 9.26 pg/ml and 5.1 pg/ml respectively (p=0.01) ( Table 2 ) (25). TIM3 concentrations were also significantly elevated at diagnosis compared to remission, 9.25 pg/ml and 5.57 pg/ml, respectively (p=0.03). In bone marrow samples, TIM3 expression was higher in AML samples than in healthy controls, 10.89 pg/ml and 5.1 pg/ml, respectively, at diagnosis (p=0.04). The expression levels of TIM3 from AML bone marrow lysates at diagnosis and in remission were not significantly different (10.8 pg/ml and 5.1 pg/ml, p=0.01).

A multi-arm open-label phase 1b study (NCT03066648) investigates combination therapy with sabatolimab (MBG453), which is an anti-TIM-3 IgG4 and a hypomethylating agent (decitabine or azacitidine) (26). Preliminary findings with just sabatolimab have shown promising survival rates in R/R AML and de novo AML patients who are not candidates for standard treatment (HMA-naive) ( Table 1 ). An analysis was performed on 28 of these patients who underwent an allogeneic HSCT. Before HSCT, 36% of patients had a complete response, and 32% had a complete molecular or complete response without hematologic recovery. 8% had a partial response or hematologic improvement, and 25% had stable disease. After allogeneic HSCT, median OS was not reached. However, the 2-year OS rate was 69%, and the 2-year recurrence-free survival rate was 64%. Regarding adverse effects, 57% experienced acute graft-vs-host disease (GVHD), 14% of which experienced grade 3/4 GVHD, where one patient died in hospice after grade 4 GVHD.

A phase 1b/2, open-label study (NCT04623216) currently recruiting aims to investigate sabotolimab monotherapy in combination with azacitidine in AML patients who received one allogeneic HSCT achieving complete remission but were minimal residual disease positive (MRD+ post-allogeneic HSCT) ( Table 1 ) (27). Results from 21 patients showed 7 patients were in complete remission (CR) and on treatment after one year of therapy. The remaining 14 had been discontinued on treatment due to relapse, AE, or treatment change. There were toxicities, with 76% of patients experiencing any toxicity and 38% experiencing grade 3 or higher toxicities. Most commonly, neutropenia and thrombocytopenia. There were 4 patients who experienced dose limiting toxicities. A follow-up dose expansion study is planned (28). Unfortunately, although there was much enthusiasm for this compound, in January 2024, Novartis discontinued the program evaluating sabatolimab in high-risk myelodysplastic syndromes as the STIMULUS-MDS trial did not meet its primary endpoints of improved complete response rates or progression-free survival (29).

VISTA (V-domain Ig suppressor of T cell activation) is a novel immune checkpoint similar to PD-1 or CTLA-4. VISTA is highly expressed in primary AML cells and is associated with a poor prognosis (30). Based on the TCGA database, VISTA was the most correlative immune checkpoint in the overall prognosis of AML patients as it had the same higher expression as in CD34+ AML cells and CD34- myeloid cells of bone marrow. VISTA helps impede T-cell activation. Hyperactive STAT3 in AML has been associated with a high expression of VISTA. One STAT3 inhibitor, W1046, suppresses AML proliferation and survival. The inhibition of STAT3 causes a downregulation of VISTA, which allows for activation of T cells. However, the molecular mechanism of how this occurs is unknown. T-cell-mediated cytotoxicity to AML cells is also boosted through anti-VISTA mAb, and anti-VISTA mAb was also shown to prolong the survival of AML in mice. In vitro and in vivo studies have also shown that the combination of W1046 and VISTA mAB caused a drastic elevation in T cell cytotoxicity in vitro and also caused upregulation of the secretion of interferon (IFN)-y, interleukin (IL)-2, and CD4+ and CD8+ T cells. Although VISTA has been more thoroughly studied in other malignancies, the role of targeting this checkpoint as an anti-leukemic therapeutic strategy remains to be seen.

CD47 was initially discovered as an antigen in human ovarian cancer and later found to be overexpressed in hematological tumors like AML (31). CD47 supports cells in evading phagocytosis by macrophages in leukemic cancer cells, and much enthusiasm has been put behind this pathway as evidenced by multiple compounds being developed to target this checkpoint in AML ( Table 1 ).

LILRB4 is a member of the leukocyte immunoglobulin-like receptor family of proteins commonly seen on myeloid lineage cells. They play an important part in cell activation and differentiation. LILRB4 is seen most commonly in monocytic AML. Working through APOE, SHP-2, uPAR, and ARG1 signaling pathways, LILRB4 activation leads to downregulation of T cell activation, aiding in cancer infiltration and immune system evasion (39). Similar to other targets discussed, LILRB4 overexpression in cancer cells compared to normal cells makes it an enticing target for immune checkpoint inhibition and other therapies. NCT04372433 is an active Phase 1 trial evaluating IO-202, a humanized monoclonal antibody blocking LILRB4 from binding to APOE and fibronectin ( Table 1 ). Part 1 of the study reported on 36 patients with R/R AML with monocytic differentiation treated with azacitidine ± Venetoclax or as monotherapy. Overall, the drug was well tolerated, with no dose-limiting toxicity observed and no study-related deaths. Unfortunately, in the monotherapy group, only one patient achieved a partial remission. In the combination group, only one patient (noted to have high LILRB4 expression) achieved CR, which was durable for 7 months as of the report. Several other patients did show blast reduction but did not achieve remission. While this trial showed limited success in general monocytic AML, patients were not screened for high LILRB4 expression. Part two of the trial will expand to look at patients with high LILRB4 expression which will hopefully yield more promising results (40). There are two other up-and-coming trials using STAR-T or CAR-T cells targeting LILRB4 that have been indexed; however, they have not started recruiting or been reported on.

CD123 is a cytokine receptor widely overexpressed in multiple hematologic cancer cells and associated with high-risk disease characteristics in adult and pediatric AML. In particular, AML cells with FLT-3 or NPM1 mutations are associated with higher levels of CD123 compared to cells with wild-type FLT3 or NPM1 (41). CD123 has become an important biomarker that can be potentially targeted in relapsed or refractory AML. CSL360 is a recombinant chimeric immunoglobulin G1 (IgG1), an anti-CD123 monoclonal antibody proven less beneficial in patients with relapsed/refractory or high-risk AML (42, 43). The phase I clinical trial (NCT00401739) assessed the efficacy and safety of CSL360 in relapsed/refractory AML cases ( Table 3 ). The study analyzed 40 patients, with 25 of the patients having relapsed AML and 8 of the patients having refractory disease. The study found that CSL360 was well tolerated, as the most common AEs of any grade were headache (32.5%), diarrhea (27.5%), nausea (27.5%), and infection (17.3%). AEs also did not increase the frequency of the dose level escalation. The study found no anti-leukemic effects as most patients had no improvement in blast percentage in BM aspirates during the study. The study found that 28/30 patients (93.3%) had persistent disease after four hours of CSL360, according to NCCN response criteria (42).

CD123 antagonistic peptides assembled with nanomicelles have also been evaluated preclinically ( Table 2 ) (16). In the study, nanomicelles were loaded with a lab-designed CD123 antagonistic peptide (mPO-6) and were investigated with CD123+ AML cell lines and a refractory AML mouse. Results showed that IV administration of mPO-6) reduced the percentage of AML cells and prolonged median survival of AML mice. It was determined that mPO-6 interferes with the axis of CD123/IL-3, which helps enhance apoptosis and prolong the median survival of AML mice.

Another preclinical study investigated SIRPα-αCD123 fusion antibodies targeting CD123 with blockade of CD47 to augment anti-CD123 activity ( Table 2 ) (44). As reviewed previously, leukemic cells have CD47, an innate immune checkpoint upregulated on the AML cell surface. The authors developed a SIRP α-αCD123 fusion antibody that enhances the leukemic stem cell clearance by disrupting CD47/SIRPα signaling to AML. In vitro, blocking assays were used to interfere with the binding of SIRPα. The SIRP α-αCD123 fusion antibody showed increased binding and targeting of CD123+/CD47+ AML cells, even in CD47+ healthy cells. In vitro experiments also showed SIRPα-αCD123 antibodies greatly enhanced AML cell phagocytosis mediated by allogeneic and autologous macrophages. Unfortunately, due to a lack of clinical response, targeting AML via monoclonal antibody therapy has lost enthusiasm.

CD33 is a receptor protein primarily expressed on leukemic blasts, and low expressions of CD33 have been seen in more complex karyotypes and translocations. Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated with calicheamicin, was first approved by the FDA in 2000 (45). However, the randomized phase III S0106 trial that evaluated GO versus no GO during induction and post-consolidation therapy in younger AML did not confirm promising results in the previous phase II study conducted on relapsed older adults with AML (46). The drug was withdrawn from the US market due to an unfavorable safety-efficacy profile. However, it was later placed back on the market in 2017 after multiple randomized controlled trials showed an improved OS as well as event-free survival when GO therapy is used in addition to induction/consolidation therapy in newly diagnosed AML patients with a safe toxicity profile.

The improvement of OS was further characterized when evaluating the cytogenetic profile of treated patients. One meta-analysis looked at five large, randomized trials, which analyzed GO in induction/consolidation chemotherapy in all ages of AML patients. Beneficial effects of GO were seen in favorable risk AML, along with a smaller benefit in intermediate-risk AML and no benefit in adverse-risk (47). Favorable cytogenetics saw an overall survival benefit regardless of age, 30.7% vs 34.6%. The survival benefit was mainly seen in the favorable cytogenetics (55.3% vs. 76.3%) and intermediate-risk patients (34.1% vs. 39.4%). Patients with adverse karyotypes did not see any benefit in overall survival.

Hepatic veno-occlusive disease (VOD), which is a clinical syndrome characterized by jaundice, painful hepatomegaly, and/or fluid retention, was reported in initial studies with GO in AML. Late manifestations of hepatic VOD include ascites and encephalopathy. In the meta-analysis, fractionated dosing using 3 mg/m2 was associated with less toxicity and equal efficacy (47). The data obtained from the fractionated dosing schedule led to the reapproval of GO (48).

C-type lectin-like molecule-1 (CLL-1) is primarily expressed on granulocytes and monocytes and, to a lesser degree, on precursors and HSCs. However, expression is seen in a large percentage of AMLs, including leukemic stem cells (49). Daver et al. evaluated the ADC DCLL9718S in 2021 in a phase I dose-escalation trial. DCLL9718S is a humanized monoclonal IgG1 anti-CLL1 antibody linked with two pyrrolobenzodiazepine (PBD) dimer drugs via a cleavable disulfide linker. Eighteen patients were treated in the study, and almost all participants experienced at least a grade 1 adverse event, with at least half being attributable to treatment. The most common adverse events were neutropenia and pneumonia, although no dose-limiting toxicity occurred, and no deaths occurred because of therapy. At the highest dose of 160 μg/kg, 2 patients began experiencing hepatotoxicity, although this may be intrinsic to PBD and not drugs targeting CLL-1. No patient achieved a complete or partial response. The trial was stopped, and there are no plans to move forward with the drug, given the poor tolerability and limited anti-leukemic effects observed (50). Several other groups have published their preclinical work as the potential of CLL-1 remains promising despite the setbacks seen with DCLL9718S.

CD123, also known as interleukin 3 receptor alpha, is another target with elevated expression in AML with the potential to target leukemic stem cells that been targeted by multiple groups. Kuvtun et al. have worked to change the cytotoxic drug component of ADCs. IMGN632 comprises a novel humanized anti-CD123 antibody, G4723A, linked to an alkylating agent, indolinobenzapine (IGN) pseudodimer (51). They previously had a DNA crosslinking agent, but as with several ADCs, toxicity became a limiting factor. IMGN632 showed potent activity against AML samples in vitro and in xenograft mouse models made from EOL-1, MOLM-13, and patient-derived samples (51). Substantially less toxicity to normal hematopoietic cells was seen. Daver et al. began a phase 1 clinical trial looking at IMGN632 in R/R AML and blastic plasmacytoid dendritic cell neoplasm, NCT03386513 (52). Of the 66 patients with R/R AML treated on protocol, 55% demonstrated a reduction in bone marrow blasts, with 20% achieving CR (N=3), CRi (N=8), or morphologic leukemia-free state (N=2). Among the 74 patients evaluated between the two groups, the most common AEs were diarrhea (30%), febrile neutropenia (27%), nausea 20%, chills (23%), and lung infection (22%). Three dose limiting toxicities occurred, one prolonged neutropenia and two reversible instances of VOD (53). Given the activity in the R/R setting, this combination is being explored in newly diagnosed AML patients expressing CD123 (54).

Talacotuzumab, a humanized CD123 monoclonal antibody, has shown potent in vitro ADCC against AML blasts, reducing leukemic cell growth in murine xenograft models (55). A multicenter phase 2/3 clinical study investigates talacotuzumab to determine the recommended phase 2 dose in AML patients. An open-label, randomized comparison of talacotuzumab in combination with decitabine versus decitabine alone was also investigated. The recommended phase 2 dose was 9mg/kg. CR was achieved in 15% of patients receiving combination therapy versus 11% in those receiving decitabine alone. Median OS was 5.36 months for combination therapy versus 7.26 months for decitabine alone. Therefore, combination therapy did not demonstrate improvement in efficacy versus decitabine alone.

C-X-C chemokine receptor type 4 (CXCR4) is an important receptor in homing hematopoietic cells to bone marrow and is expressed highly in many hematological malignancies, identifying another favorable immunotherapeutic target in AML. However, utilizing CXCR4 as a target does have some challenges as it is also relatively expressed on normal hematopoietic cells and other tissues. Current work on a CXCR4 ADC is all preclinical, but Costa et al. showed promising work empirically deriving optimal ADCs (56). They optimized ADCs by varying linker-payload cleavability, drug-to-antibody ratio, affinity, and Fc format to maintain a tolerable safety profile while targeting more broadly expressed proteins. Their ADC which targets CXCR4 using auristatin greatly increased survival in MV4-11 AML mouse models, among other cancers. They observed significant differences in efficacy between different constructs of the ADC. More work must be done to expand this to other ADCs and see how this translates into targeting CXCR4 in clinical settings (56).

Fms-like tyrosine kinase 3 (FLT3) is a class III receptor tyrosine kinase expressed on leukemic stem cells and blast cells of most AML patients with significantly higher expression levels than healthy tissue. Additionally, the presence of internal tandem duplication (ITD) mutation of FLT3 (FLT3-ITD) has a reportedly higher relapse risk and poorer outcome in AML patients (57). The 2023 Roas M. et al. preclinical study investigated 20D9-ADC (an ADC targeting FLT3) in vivo and in vitro models. In vitro, 20D9-ADC mediated potent cytotoxicity to FLT3 or FLT3-ITD expressing Ba/F3 cells, AML cell lines, and FLT3-ITD positive patient-derived xenograft AML cells ( Table 2 ). It also showed no severe hematotoxicity in vitro colony formation assays when using concentrations cytotoxic in AML cell line treatment. Additionally, 20D9-ADC treatment in vivo resulted in significant tumor reduction and complete remission in AML xenograft models (57).

FLT3 mutations are observed in around 25% of adult AML patients and 30% in those over 55 and are generally associated with poor outcomes (60). FLT3 also has limited expression in normal tissue, primarily found in early hematopoietic progenitors and leukemia blasts. Given this, FLT3 has been a promising target for several therapeutic options, including tyrosine kinase inhibitors and BiTEs (61). Two FLT3 BiTE molecules, one with a half-life extending moiety and one without, were analyzed by Brauchle et al. in 2020. They evaluated bulk leukemia cells from bone marrow or peripheral blood from 318 newly diagnosed or relapsed AML patients and found that 78% showed increased FLT3 protein expression. From there, they exposed FLT3 positive cell lines, such as MOLM-13, EOL-1, and MV4-11, to the BiTEs leading to cytotoxicity, whereas FLT3 negative cell lines, such as K562, showed relatively little response. Mouse xenograft models created using MOLM-13 and EOL-1 cells followed by injection of human CD3+ T cells showed a significant reduction in tumor growth with weekly FLT3 BiTE treatment. They also showed a reduction of FLT3 expression in cynomolgus monkeys with reasonable pharmacokinetics. The addition of PD-1 blockade also showed enhancement of cytotoxicity. This has been noted in other BiTE trials and is thought to be due to increased activation of T-cells inducing PD-1 expression (58).

APVO436-5001 (NCT03647800) is an ongoing phase 1b dose escalation trial looking at APVO436, a novel bispecific anti-CD123 and anti-CD3 ADAPTIR molecule. The bispecific antibody has shown anti-leukemia activity in murine xenograft models of AML (62). Nine patients with R/R AML were treated in the study; and one patient achieved a prolonged stable disease, and two had a partial response that later progressed to a complete response (62). The most common grade 3 or greater adverse events likely APVO436-related were grade 3–4 cytokine release syndrome occurring in 4 of 46 patients (8.7%), grade 3–4 anemia occurring in 2 of 46 patients (4.3%), and infusion-related reaction occurring in 2 of 26 patients (4.3%). Further evaluation of this compound is ongoing.

Flotetuzumab (MGD006) is a bispecific antibody-based molecule to CD3 and CD123 in DART format. Preclinical models have investigated flotetuzumab mediated target-effector cell association, T-cell activation and proliferation, and potent killing in AML blasts both in vitro and in vivo. A phase 1/2 clinical study of flotetuzumab in R/R AML(NCT02152956) showed that of primary induction failure patients and early relapse patients, 26.7% achieved complete remission or complete remission with partial hematologic recovery. ORR was 30.0% with a median OS of 10.2 months, a 6-month survival rate of 75%, and a 12-month survival rate 50% (63). Unfortunately, due to underwhelming responses, the development of this product was discontinued (64).

One mechanism of resistance to BiTE therapy has been a loss of tumor-associated antigens. It was hypothesized that targeting more than one tumor-associated antigen could lead to a reduced frequency of relapse (65). The study used a half-life extended CD123-FLT3 BiTE molecule in vitro, mouse xenografts, and non-human primate tolerability studies. A survival benefit of >3 weeks was seen in the xenograft model (65). Additionally, both arms of the molecule were active, as survival benefits in mice with single positive tumors could not be calculated due to the high survival. Furthermore, follow-up blood tests showed a decrease in FLT3 mRNA. Repeat dosing was also not tolerated, and cytokine release was observed. It is hypothesized that CD123 expression would be increased with the cytokine release following repeat dosing.

CD33 is expressed in >99% of AML cases, and BiTE has been effective in relapsed/refractory acute lymphoblastic leukemia. AMG 330 is a BiTE that binds to CD33 and CD3 on T cells and helps cause T-cell mediated destruction of CD33+ cells. In the presence of AML cells, AMG 330 induced the release of IFN-y, TNF, IL-2, IL-10, and IL-6 (66).

Ravandi et al. treated 35 relapsed/refractory AML patients with 12 different dose levels of AMG 330 ranging from 0.5-480 μg/d in a phase 1 study ( Table 3 ). Of the thirty-five patients treated, thirty-one ultimately discontinued treatment. The majority of patients stopped therapy due to disease progression (n=24). Five patients discontinued therapy due to adverse events (two treatment-related), and two at the patient’s request. Overall, 23 adverse events occurred, 15 of which were treatment related. Most commonly, cytokine release syndrome (n=11), febrile neutropenia (n=6), pneumonia (n=4), leukopenia (n=3), and thrombocytopenia (n=2). Five patients demonstrated a response: two patients achieved CR, two achieved CRi, and had a morphological leukemia-free state (67).

CAR-T is of great interest in AML. However, there remains a need for identifiable targets ubiquitously expressed in AML yet dispensable ( Table 4 ) (68).

Similar to CAR-T cells, TCR-T cells are engineered T cells. However, instead of a synthetic receptor (CAR), they express a naturally occurring T cell receptor (TCR) that targets specific tumor antigens. The targeted antigens must be highly expressed on leukemic cells but limited to no expression on healthy hematopoietic cells. If the chosen antigen is found in healthy cells, TCR-T has to be short-lived. Several tumor-associated antigens (TAA) have been identified for preclinical trials with TCR-T. These include categories: overexpressed antigens (i.e. surviving, TERT), lineage-restricted antigens (i.e., WT1), minor histocompatibility A (HA)-1, neoantigens (i.e., NPM1 and CBFB-MHY11), and cancer-testis antigen (i.e., NY-ESO-1, MAGE, PRAME) (83).

A 2017 preclinical study showed that TERT TCR-T efficiently lyses AML cells in vitro and inhibits tumor growth in the AML xenograft model (84). A 2018 preclinical study showed that HA1 TCR-T demonstrated potential killing in AML/LCL cell lines (85). A 2020 preclinical study using CBFB-MHY11 for TCR-T exhibited potent antileukemic activity against AML cells and in the xenograft model (86). Lastly, a 2020 preclinical study with HLA-DPB1 TCR demonstrated highly lysed AML in vitro and in xenograft model (87). Most recent clinical trials utilize WT1 as the TAA. A phase I clinical trial (NCT01640301) used EBV-specific donor CD8+ T cells inserted with WT1-specific TCR amongst 12 AML patients with high risk for HCT-related relapse. High-risk patients were identified by genetics, including HLA-A*0201 expression. Relapse-free survival was achieved in 100% of patients with a median of 44 months after infusion (88). Regarding safety, two patients developed grade III CRS. Eight patients developed grade III lymphopenia, and five patients developed grade IV lymphopenia. Two patients developed grade III thrombocytopenia, one exhibited grade III reduced neutrophil count, and one exhibited grade IV reduced neutrophil count. Lastly, seven patients developed grade III anemia.

Tumor-infiltrating lymphocytes infiltrate the tumor microenvironment and have the potential to recognize and kill cancer cells (89). One study investigated ex vivo isolation, expansion, and bioengineering of specific subsets of tumor-infiltrating lymphocytes (TILs) from the bone marrow of AML patients (90). Two subsets of TILS CCR7+CD95-/or and CD62L+CD45RA+ have been shown to possess anti-tumor activity (90). Researchers were able to isolate the desired TILS through the use of magnetic-activated cell sorting and flow cytometry.

Novel approaches are being analyzed to target AML while sparing normal hematopoiesis. Researchers also used bioengineering of TILs to enhance anti-tumor activity by using gene-edited hematopoietic stem and progenitor cells (HSPCs) to regenerate an antigen-negative myeloid system (91). They genetically modified TILs to express a chimeric antigen receptor (CAR) that targeted CD33, which is highly expressed in AML. The study found that in vitro differentiated CD33 KO HSPCs had reduced levels of CD33 protein expression (27% ± 4%) compared to controls (92% ± 3%) (91). Mice were injected with control, or CD33 KO HSPCs, and their human cell engraftment was followed over time in peripheral blood. It was found that mice who were injected with CD33 KO HSPC had diminished expression of CD33 sustained over time. The total number of CD45+ cells and myeloid subsets remained nearly identical between the two groups. The CAR-modified TILS showed enhanced cytotoxicity against AML cells in vitro, which suggests the potential ability to improve the efficacy of TIL-based immunotherapy in AML.

TIL-based treatments for AML are in the early stages of development with multiple possible beneficial combinational therapeutic approaches. TILs combined with hypomethylating agents and checkpoint inhibitors may enhance their anti-tumor activity.

Natural killer (NK) cells play an enormous role in innate immunity by targeting infectious agents and tumor cells. The interplay between NK cells and cytokine secretion is dictated by activating or inhibitory receptors that bind ligands on these target cells, ultimately allowing NK cell activation and killing targets (92). In AML, malignant cells evade the immune system by suppressing NK cell function. NK cell therapy is a novel immunologic approach to treatment in AML, in which suppression is prevented, allowing these cells to perform cell-specific targeted killing.

There have been challenges with harvesting NK cell lines for therapy. NK cells from donor peripheral blood mononuclear cells (PBMCs) express markers like CD16, NKG2D, NKp44, and NKp46, which allow them to recognize and kill non-self-cells such as tumor cells. Unfortunately, the quantity of NK cells in peripheral blood is low and not cost- or time-effective. Induced pluripotent stem cells are a good source of NK cells. However, they express low levels of CD16, therefore making them less cytotoxic. NK-92 cell lines are an alternative option. They are immortalized NK lymphoma cells; but have their own safety concerns (92).

CD94-NKG2A is another target for immune checkpoint therapy. It is an inhibitory receptor on NK cells and CD8+ T cells that inhibits the cytotoxic function of these respective cells (93). This receptor is inhibited by HLA-E, a non-classical MHC class I molecule found on normal and neoplastic hematopoietic cells. The 2016 Ruggeri, L. et al. study demonstrated that the humanized anti-NKG2A antibody converts NKG2A+ NK cells into effector NK cells that induce tumor cell death by killing most HLA-E+ NK resistant lymphohematopoietic cells such as dendritic cells, myeloid cells, B and T lymphocytes, and leukemic cells including AML amongst other cell types.

Recently, interest in memory NK cells has grown. These cells have differentiated in response to IL-12, IL-15, and IL-18 cytokines. These cells are specifically called cytokine-induced memory-like differentiation (ML NK) and have shown enhanced effector function and prolonged survival in various leukemic models (94). A phase I/II clinical trial investigates the best dose and side effects of activated natural NK cells in treating patients with R/R AML and R/R MDS. Chemotherapy will be given before donor NK cell infusions, which will slow the growth of cancer cells and prevent the recipient’s immune system from rejecting these donor cells. NK infusion will be from a related MHC-haploidentical donor. These modified NK cells may help strengthen the immune response to targeting and killing leukemic cells. Aldesleukin, an IL-2 cytokine, will be administered for two weeks following NK infusion to support NK growth. The study had 15 patients, 7 of whom achieved complete remission, supporting the use of allogeneic ML NK cells as therapy for relapsed AML. The caveat is that allogeneic donor NK cells were eliminated in several weeks after receiving T-cell recovery. Therefore, ML NK cell persistence could not be investigated (94).

A phase II clinical trial does study ML NK cell persistence. Patients with relapsed AML who received haploidentical hematopoietic cell transplants also received ML NK cells from their HCT donors, preventing NK cell allo-rejection. On day 28, complete remission was achieved in more than 90% of patients. Patients who have relapsed with AML after HCT and who received salvage therapy followed by T cell donor lymphocyte infusion (DLI) showed poorer outcomes. Therefore, the effects of donor ML NK infusion added to salvage therapy and T cell DLI for relapsed AML patients after HSCT were studied. The salvage therapy was fludarabine, cytarabine, and granulocyte-colony stimulating factor. T cell DLI and ML NK infusions were derived from the same HCT donor. The NK infusions were safe, and no patient experienced cytokine release syndrome. This regimen was well tolerated; only one patient exhibited mild skin GVHD. Within one month, 4 of 9 patients achieved complete remission, and 2 achieved partial remission. On day 100, two more patients reached complete remission. Additionally, with this immune-compatible therapy, ML NK cells persisted in PB and bone marrow for at least three months in most patients. These ML NK cells drawn from recipient PB, or bone marrow displayed anti-leukemic characteristics within in vitro assays and retained their phenotype over time (95).

Edited T cells are a significant area of study for CAR-T Therapy, however, this approach faces several limitations, including the availability of autologous T cells, complications with therapies, and resistance (96–98). The tumor killing ability of the T cells is also suppressed by increasing Treg subsets and senescent and exhausted T compartment (9, 99).

Research has demonstrated that mouse OP9 stromal cells expressing Notch logan DLL1 can induce T cell lineage commitment in vitro from natural mouse hematopoietic progenitor cells (100). This was later expanded with the use of human blood progenitor cells in the presence of OP9 stromal cells expressing human NOTCH1 ligand DLL1 (101). This work has illustrated the ability to generate T-cells from hematopoietic stem cells utilizing an in vitro co-culture system.

One of the future goals is to develop a method capable of generating immunocompetent and therapeutic T lymphopoiesis from unlimited and gene-editable PSCs (102). Pluripotent stem cells have a unique advantage, with efficient gene editing and self-renewal properties in vitro, making them valuable candidates for T-cell generation (103). Runx1 and Hoxa9, during the early stages of endothelial-to-hematopoietic transition to hematopoietic progenitor maturation in the PSC differentiation scheme in vitro, produced a type of induced hematopoietic progenitor cells (iHPCs) that could home to the thymus, engraft, and generate induced T cells (iT cells) with diverse TCRαβ repertoire in immunodeficient mice (102). These iT cells helped restore immune surveillance function in immunodeficient mice and also possessed anti-tumor activities in vivo when engineered to carry tumor antigen-specific TCR at the PSC stage. These findings help create a potential link to the unlimited and editable PSC source and T cell-based immunotherapy, potentially overcoming the current limitations faced by CAR-T therapies.

High WNT1 expression is associated with poor prognosis, which is often seen in AML. Anguille et al. reported from their phase II trial investigating dendritic cell vaccination. The study had 30 AML patients who were at increased risk for relapse were vaccinated with dendritic cells that were electroporated with WT1 mRNA. There were 13 of 30 study participants who responded to treatment, with 9 achieving molecular remission measures by normalization of WT1 levels and 4 showing disease stabilization. The five-year overall survival of the responders was 53.8% vs 25.0% in the nonresponder group (105). While this initial data is promising, larger control trials will need to be done, given that this study primarily compared nonresponders and responders with a relatively small sample size. Ogasawara et al. also studied 9 AML and 2 acute lymphoblastic leukemia (ALL) patients treated with peptide-loaded DCs in 2022. They saw an increase in progression-free survival, although no statistically significant increase in overall survival. They also observed a decrease in regulatory T cells following vaccination, suggesting DC vaccination may contribute to a reversal of immunosuppression.

Some groups have tried to increase the expression of these antigens on dendritic cells, with Dagvadori et al. creating a WTI-DEC205 fusion protein. This chimeric anti-hDEC205-WT1_91-138 directly induced ex-vivo responses when fusion protein-loaded DC were co-incubated with T-cells. Additionally, the co-incubated T-cells showed a robust cytotoxic activity lysing WT1-overexpressing THP-1 leukemia cells while sparing WT1-negative hematopoietic cells in vitro (104).

Several other phase 1 trials have tried combining multiple TAAs with multiple trials giving vaccines with DCs loaded with WT1 and PRAME. Lichtenegger et al. examined 10 patients treated with vaccines using WT1 and PRAME. They saw a greater immune response in those under 65, but this did not reach a statistically significant difference between responder and nonresponder OS (106). Floisand, Y et al. looked at 20 patients who had a 5-year OS of 75% but did not directly compare this to a control or nonresponder group (106). Loosdrecht et al. looked at 12 patients treated with DCP-001, now known as vididencel, a dendritic vaccine using WT1 and PRAME. They observed an immune response in 7 of the 12 patients. Patients who responded had significantly increased OS (107, 108). A follow-up study, ADVANCE-II (NCT03697707) has preliminary results from 20 patients reported at ASH 2023. They reported findings suggesting vaccinations may increase dendritic cell populations, leading to increased T-cell activity against tumors; 2-year RFS and OS were estimated at 59% and 73%, respectively (109, 110).

NY-ESO-1 has been a promising target in many cancers, given its expression profile in healthy tissue, mostly limited to embryonic development and germ cells. However, expression is seen in many cancers, and treatment with hypomethylating agents such as decitabine can enhance this expression by acting on the hypermethylated promoter of NY-ESO-1 (111). Griffith et al. looked to take advantage of this by combining decitabine with a NY-ESO-1 fusion protein vaccine in 9 MDS patients (112). A total of 7 patients completed the entire treatment course, and two discontinued study treatments due to events deemed unrelated to the vaccine. All 7 patients showed NY-ESO-1 expression induction. Of those 7, 6 showed NY-ESO-1 specific CD4+ cell responses, and 4 showed NY-ESO-1 specific CD8+ cell responses. Dendritic cells were again thought to be a key component in T-cell activation, with increased CD141^Hi DCs at diagnosis being associated with immune response (112).

NCT01956630 was a 2-stage, phase 1 trial that looked at using genetically modified DC carrying TAAs Survivin and MUC1 and an RNA interference moiety to suppress SOCS1. In Stage 1, safety was assessed, with 23 patients with relapsed AL receiving the intervention and 25 receiving standard donor lymphocytes. The treatment was well tolerated, with no documented stage 3 or 4 GVHD. An increase in the 3-year OS was seen 48.9% in the intervention group vs 27.5% in the control group. Stage 2 looked at 12 relapsed AML patients, with 83% achieving complete remission (113).